Edoxaban: Phase III started

Daiichi Sankyo began the open-label, international Phase III ENSURE-AF trial to compare 30 or 60 mg daily oral edoxaban vs. 100 mg/kg enoxaparin plus 1 or 2.5 mg warfarin in over 2,200 patients with non-valvular AF undergoing electrical cardioversion. ...